20
Apr
Inactivated vaccines, while highly safe, are extremely complex and expensive to manufacture, resulting in lower yields when compared to live virus vaccines. The vaccine has received Emergency Use Authorisations (EUA) in several countries across the globe with another 60 in process including the US. Pricing for international markets and supplies to governments under EUAs have been established between $15 and $20 per dose. To further increase capacities, Bharat Biotech has partnered with Indian Immunologicals (IIL) to manufacture the drug substance for Covaxin. The technology transfer process is underway and IIL has the capabilities and expertise to manufacture inactivated viral vaccines…